Although an association between APOBEC3B expression in breast cancer cells and sensitivity to another CHK1 inhibitor, CCT244747, was previously reported [29], that agent was absent from both the CCLE and the GDSC drug sensitivity data sets. The gene discussed is APOBEC3B; the disease is breast carcinoma.